Clinical Trial Update: Effect of Spironolactone and Vitamin E in Patients With Nonalcoholic Fatty Liver Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating spironolactone and vitamin E for nonalcoholic fatty liver disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Spironolactone (spironolactone)
• Vitamin E (tocopherol)

Snippet

Sponsor: Aristotle University Of Thessaloniki | Conditions: Fatty Liver, Steatohepatitis | Phase 2 | Status: COMPLETED